{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:22:01Z","timestamp":1787638921225,"version":"build-2736575974"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To systematically assess the prognostic significance of baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose positron emission tomography\/computed tomography ([\n                      <jats:sup>18<\/jats:sup>\n                      F] FDG PET\/CT) metabolic parameters in patients with non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor (ICI) therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search of five core databases was conducted up to March 2026. Relevant data concerning NSCLC patient characteristics, metabolic [\n                      <jats:sup>18<\/jats:sup>\n                      F] FDG PET\/CT parameters, and survival outcomes were extracted. Hazard ratios (HRs) were pooled to assess the prognostic significance of maximum standardised uptake value (SUVmax), mean standardised uptake value (SUVmean), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) regarding overall survival (OS) and progression-free survival (PFS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 33 studies were eligible for inclusion. Univariable analysis showed no prognostic value for SUVmax and SUVmean. Conversely, elevated MTV and TLG were associated with inferior PFS (MTV: HR\u00a0=\u00a01.71,95% CI: 1.39\u20132.11; TLG: HR\u00a0=\u00a01.84, 95%CI: 1.31-2.57) and OS (MTV: HR\u00a0=\u00a01.80, 95%CI: 1.40-2.33; TLG: HR\u00a0=\u00a01.92, 95%CI: 1.18-3.12) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01), particularly when cut-off values ranged of 50-100cm\n                      <jats:sup>3<\/jats:sup>\n                      for MTV (PFS: HR\u00a0=\u00a01.71, 95%CI: 1.16-2.52; OS: HR\u00a0=\u00a02.23, 95%CI: 1.42-3.51). Multivariable Cox regression analysis further identified MTV as a robust independent predictor of both PFS (HR\u00a0=\u00a01.21, 95%CI: 1.07-1.36) and OS (HR\u00a0=\u00a01.14, 95%CI: 1.03-1.26). While TLG maintained independent prognostic significance for PFS (HR\u00a0=\u00a01.46, 95%CI: 1.10-1.94), it failed to reach statistical significance regarding OS (HR\u00a0=\u00a01.00, 95%CI: 0.99-1.01) (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.01). Notably, subgroup analyses demonstrated that the prognostic efficacy of MTV and TLG was further pronounced in patients presenting with Stage IV disease, those undergoing first-line treatment, or those managed with chemoimmunotherapy regimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline MTV is an independent prognostic factor for PFS and OS in NSCLC patients treated with ICIs, with a cut-off value within the range of 50\u2013100 cm\u00b3 demonstrating optimal predictive performance. In contrast, the predictive significance of TLG for OS was not maintained after multivariable adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261375745<\/jats:ext-link>\n                      , identifier CRD420261375745.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1896967","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:34:59Z","timestamp":1787636099000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinwen","family":"Han","sequence":"first","affiliation":[{"name":"The first Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital)","place":["Lanzhou, Gansu, China"]},{"name":"PET\/CT Center, Gansu Provincial Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The first Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital)","place":["Lanzhou, Gansu, China"]},{"name":"PET\/CT Center, Gansu Provincial Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhong","family":"He","sequence":"additional","affiliation":[{"name":"The first Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital)","place":["Lanzhou, Gansu, China"]},{"name":"PET\/CT Center, Gansu Provincial Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Wang","sequence":"additional","affiliation":[{"name":"The first Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital)","place":["Lanzhou, Gansu, China"]},{"name":"PET\/CT Center, Gansu Provincial Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.250448","article-title":"Preoperative contrast-enhanced CT features associated with occult lymph node metastasis in early-stage solid non-small cell lung cancer","volume":"8","author":"Feng","year":"2026","journal-title":"Radiol Imaging Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.10.016","article-title":"Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists","volume":"106","author":"Mazzone","year":"2012","journal-title":"Respir Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6357-1","article-title":"Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma","volume":"25","author":"Kurahara","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa022136","article-title":"Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography","volume":"348","author":"Lardinois","year":"2003","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","article-title":"Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer","volume":"39","author":"Liao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.003","article-title":"Prognostic value of pretreatment FDG-PET parameters in high-dose image-guided radiotherapy for oligometastatic non-small-cell lung cancer","volume":"19","author":"Chin","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/rlu.0000000000001886","article-title":"Role of various metabolic parameters derived from baseline 18F-FDG PET\/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.01.024","article-title":"Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib","volume":"94","author":"Winther-Larsen","year":"2016","journal-title":"Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.036","article-title":"Metabolic tumor burden predicts for disease progression and death in lung cancer","volume":"69","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2014"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"Cinema: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13362","DOI":"10.1038\/s41598-019-50079-2","article-title":"18F-FDG uptake in PET\/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer","volume":"9","author":"Takada","year":"2019","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03150-9","article-title":"The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors","volume":"146","author":"Castello","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000023815","article-title":"Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET\/CT","volume":"99","author":"Park","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic \u00b98F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061251","article-title":"Impact of antibiotic therapy and metabolic parameters in non-small cell lung cancer patients receiving checkpoint inhibitors","volume":"10","author":"Castello","year":"2021","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211068732","article-title":"Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy","volume":"14","author":"Kim","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17588359221138386","DOI":"10.2139\/ssrn.4114254","article-title":"Tumor glycolytic profiling through 18F-FDG PET\/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC","volume":"14","author":"Silva","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/mnm.0000000000001737","article-title":"18 F-FDG PET\/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy","volume":"44","author":"Feng","year":"2023","journal-title":"Nucl Med Commun"},{"key":"B29","article-title":"Construction of a prognostic nomogram combining PET\/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy","volume":"43","author":"Kong","year":"2023","journal-title":"J South Med Univ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005910","article-title":"Prognostic value of 18F-FDG PET\/CT in neoadjuvant PD-1 inhibitor-treated NSCLC: A five-year follow-up study","volume":"50","author":"Tao","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B31","article-title":"The value of 18 F\u2043FDG\u2043PET\/CT imaging parameters combined with se\u2043rum miR\u2043345 and miR\u204320a in predicting the efficacy and prognosis of immune therapy in advanced non\u2043small cell lung cancer","volume":"44","author":"Gao","year":"2025","journal-title":"J Clin Radiol"},{"key":"B32","unstructured":"The value of 18F-FDG PET\/CT imaging in predicting the efficacy of PD-1\/PD-L1 immune checkpoint inhibitors in advanced non-small cell lung cancer\n          \n          \n            \n              Luo\n              H\n            \n            \n              Li\n              L\n            \n            \n              Wang\n              J\n            \n          \n          \n          2025"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082234","article-title":"Association of the metabolic score using baseline FDG-PET\/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab","volume":"12","author":"Seban","year":"2020","journal-title":"Cancers (Bsl)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071634","article-title":"Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): A real world experience","volume":"13","author":"Monaco","year":"2021","journal-title":"Cancers (Bsl)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13360","article-title":"Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer","volume":"17","author":"Icht","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.02.003","article-title":"Disease burden on PET predicts outcomes for advanced NSCLC patients treated with first-line immunotherapy","volume":"23","author":"Andraos","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236096","article-title":"First-line pembrolizumab mono- or combination therapy of non-small cell lung cancer: Baseline metabolic biomarkers predict outcomes","volume":"13","author":"Lang","year":"2021","journal-title":"Cancers (Bsl)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15032","article-title":"Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET\/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors","volume":"14","author":"Rizzo","year":"2023","journal-title":"Thorac Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111198","article-title":"Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy","volume":"170","author":"Kifjak","year":"2024","journal-title":"Eur J Radiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2025.106915","article-title":"Prediction of PD-L1 expression in NSCLC patients using PET\/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients","volume":"86","author":"Peng","year":"2025","journal-title":"Clin Radiol"},{"key":"B41","unstructured":"SUVmax-IPI as a new prognostic index in metastatic non-small cell lung cancer patients receiving nivolumab\n          \n          \n            \n              Kolk\u0131ran\n              N\n            \n            \n              Erdo\u011fan\n              AP\n            \n            \n              \u015eahbazlar\n              M\n            \n          \n          \n          2025"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030725","article-title":"Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer","volume":"9","author":"Hashimoto","year":"2020","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14990","DOI":"10.1038\/s41598-020-71735-y","article-title":"Tumor metabolic volume by f-18-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 >= 50%","volume":"10","author":"Yamaguchi","year":"2020","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.03.001","article-title":"The value of 18F-FDG PET\/CT in predicting the response to PD-1 blocking immunotherapy in advanced NSCLC patients with high-level PD-L1 expression","volume":"22","author":"Vekens","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000434","article-title":"Prognostic potential of metabolic activity on 18 F-FDG accumulation in advanced NSCLC receiving combining chemotherapy plus PD-1 blockade","volume":"45","author":"Hashimoto","year":"2022","journal-title":"J Immunother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109728","article-title":"Pretreatment 18-FDG-PET\/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy","volume":"185","author":"Grambozov","year":"2023","journal-title":"Radiother Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by 18F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246095","article-title":"Predictive value of baseline FDG-PET\/CT for the durable response to immune checkpoint inhibition in NSCLC patients using the morphological and metabolic features of primary tumors","volume":"14","author":"Kudura","year":"2022","journal-title":"Cancers (Bsl)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2020-0042","article-title":"18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab","volume":"54","author":"Valentinuzzi","year":"2020","journal-title":"Radiol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000645","article-title":"Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study","volume":"8","author":"Chardin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133117","article-title":"The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (NSCLC) in radiological progression during treatment with nivolumab","volume":"13","author":"Bauckneht","year":"2021","journal-title":"Cancers (Bsl)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01694-5","article-title":"Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab","volume":"36","author":"Eude","year":"2022","journal-title":"Ann Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B54","unstructured":"NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 4.2024"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1477275","article-title":"Baseline (18)F-FDG PET\/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer","volume":"12","author":"Zheng","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1014063","article-title":"Prognostic value of (18)F-FDG PET\/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Ling","year":"2022","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1739983","article-title":"Enzymatic and microenvironmental regulation in adenosine metabolism-mediated immunosuppression","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040992","article-title":"Hypoxia-driven immune escape in the tumor microenvironment","volume":"9","author":"Vito","year":"2020","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951557","article-title":"Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061474","article-title":"Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer","volume":"9","author":"Flieswasser","year":"2020","journal-title":"Cells"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20110432.CCR\u201124\u20111993","article-title":"Metabolic tumor volume assessed by 18F FDG-PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates","volume":"31","author":"Dall'Olio","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:35:01Z","timestamp":1787636101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2026.1896967"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1896967","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1896967"}}